179 related articles for article (PubMed ID: 32345483)
1. COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause.
Fernandez-Gutierrez B
Reumatol Clin (Engl Ed); 2020; 16(4):253-254. PubMed ID: 32345483
[No Abstract] [Full Text] [Related]
2. Molecular mimicry may explain multi-organ damage in COVID-19.
Angileri F; Legare S; Marino Gammazza A; Conway de Macario E; Jl Macario A; Cappello F
Autoimmun Rev; 2020 Aug; 19(8):102591. PubMed ID: 32535095
[No Abstract] [Full Text] [Related]
3. Covid-19 and autoimmunity.
Ehrenfeld M; Tincani A; Andreoli L; Cattalini M; Greenbaum A; Kanduc D; Alijotas-Reig J; Zinserling V; Semenova N; Amital H; Shoenfeld Y
Autoimmun Rev; 2020 Aug; 19(8):102597. PubMed ID: 32535093
[No Abstract] [Full Text] [Related]
4. [Not Available].
Balavoine JF
Rev Med Suisse; 2020 May; 16(695):1126. PubMed ID: 32462848
[No Abstract] [Full Text] [Related]
5. Surviving COVID-19: A disease tolerance perspective.
Ayres JS
Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
[No Abstract] [Full Text] [Related]
6. Immunomodulation in COVID-19.
Ingraham NE; Lotfi-Emran S; Thielen BK; Techar K; Morris RS; Holtan SG; Dudley RA; Tignanelli CJ
Lancet Respir Med; 2020 Jun; 8(6):544-546. PubMed ID: 32380023
[No Abstract] [Full Text] [Related]
7. SARS-CoV-2 positivity in a discharged COVID-19 patient: a case report.
Li J; Long X; Fang X; Zhang Q; Hu S; Lin Z; Xiong N
Clin Microbiol Infect; 2020 Aug; 26(8):1115-1117. PubMed ID: 32360448
[No Abstract] [Full Text] [Related]
8. Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient.
Monneret G; de Marignan D; Coudereau R; Bernet C; Ader F; Frobert E; Gossez M; Viel S; Venet F; Wallet F
Cell Mol Immunol; 2020 Sep; 17(9):1001-1003. PubMed ID: 32728202
[No Abstract] [Full Text] [Related]
9. [Not Available].
Fumeaux T
Rev Med Suisse; 2020 Nov; 16(714):2190. PubMed ID: 33174705
[No Abstract] [Full Text] [Related]
10. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.
Vojdani A; Kharrazian D
Clin Immunol; 2020 Aug; 217():108480. PubMed ID: 32461193
[No Abstract] [Full Text] [Related]
11. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
12. [Not Available].
Meylan P
Rev Med Suisse; 2020 Nov; 16(714):2190-2191. PubMed ID: 33174706
[No Abstract] [Full Text] [Related]
13. HIV and SARS-CoV-2: points to consider to face this new pandemic.
Prieto Pozo AA; Salvador Sagüez FLD
Medwave; 2020 Oct; 20(9):e8049. PubMed ID: 33141814
[TBL] [Abstract][Full Text] [Related]
14. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
Demaria O; Carvelli J; Batista L; Thibult ML; Morel A; André P; Morel Y; Vély F; Vivier E
Cell Mol Immunol; 2020 Sep; 17(9):995-997. PubMed ID: 32612152
[No Abstract] [Full Text] [Related]
15. Leukotrienes, a potential target for Covid-19.
Citron F; Perelli L; Deem AK; Genovese G; Viale A
Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
[No Abstract] [Full Text] [Related]
16. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.
Liu X; Cao W; Li T
Front Immunol; 2020; 11():1660. PubMed ID: 32760407
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.
Wu Q; Chu Q; Zhang H; Yang B; He X; Zhong Y; Yuan X; Chua MLK; Xie C
Cancer Commun (Lond); 2020 Aug; 40(8):374-379. PubMed ID: 32666636
[No Abstract] [Full Text] [Related]
18. Targeting inflammation and cytokine storm in COVID-19.
Huang Q; Wu X; Zheng X; Luo S; Xu S; Weng J
Pharmacol Res; 2020 Sep; 159():105051. PubMed ID: 32603772
[No Abstract] [Full Text] [Related]
19. Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study.
Favresse J; Eucher C; Elsen M; Laffineur K; Dogné JM; Douxfils J
Clin Chem Lab Med; 2020 Sep; 58(10):e193-e196. PubMed ID: 32639942
[No Abstract] [Full Text] [Related]
20. [Not Available].
Nau JY
Rev Med Suisse; 2020 Jun; 16(696):1174-1175. PubMed ID: 32496708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
